GT Metabolic Solutions Raises Series C Led By J.P. Morgan Life Sciences Private Capital
Article excerpt
Highlighted: the sentence this signal was extracted from
GT Metabolic Solutions has secured a Series C growth investment from J.P. Morgan Life Sciences Private Capital to accelerate commercialization of its magnetic anastomosis technology. The financing will support the company's global commercial launch and expansion into additional surgical and therapeutic applications, including endoscopic and colorectal procedures. GT Metabolic develops a linear magnetic anastomosis system that creates gastrointestinal connections without incisions, sutures, or staples. The technology uses magnetic compression to create anastomoses while avoiding permanent foreign material that could interfere with healing. The system can be used with endoscopic, robotic, or laparoscopic surgical approaches. GT Metabolic said gastrointestinal anastomotic procedures can result in serious complications such as leaks and bleeding, which can lead to sepsis, hospital readmission, and death. The company's magnetic platform is designed to create seamless connections while preserving natural biology and potentially reducing complication rates. GT Metabolic was the first company to receive both an FDA De Novo grant and 510(k) clearance for magnetic technology used to create compression anastomoses. The J.P. Morgan financing represents the company's first institutional financing partnership. GT Metabolic plans to use the proceeds for product development, surgeon...
Keep reading with a free account
The rest of this article, and every signal for JPMorgan, is in your free account.
